William Tap, MD
Enriched profileChief, Sarcoma Medical Oncology Service (Section Chief, Sarcoma Oncology, Melanoma and Sarcoma Service) · Memorial Sloan Kettering Cancer Center
William Tap is Chief, Sarcoma Medical Oncology Service (Section Chief, Sarcoma Oncology, Melanoma and Sarcoma Service) at Memorial Sloan Kettering Cancer Center. OpenAlex indexes 929 publications with 25,942 citations (h-index 75); ClinicalTrials.gov lists 10 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 14 Oct 2026
William D. Tap, MD, is Chief, Sarcoma Medical Oncology Service (Section Chief, Sarcoma Oncology, Melanoma and Sarcoma Service) at Memorial Sloan Kettering Cancer Center. The public record shows 929 publications with 25,942 citations (h-index 75), centered on Sarcoma. It also documents an investigator role on 10 registered clinical trials, industry payments reported by 20 companies, 2 NIH-funded awards (2018–2026).
- Most recent indexed publication: 2026 · Clinical cancer research
- Top research focus: Sarcoma
- 10 registered trials on ClinicalTrials.gov
- Open Payments reporting from 20 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 45 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 10 registered studies on ClinicalTrials.gov. The most recent:
- A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
Sponsor: Avacta Life Sciences Ltd
- Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Sponsor: National Cancer Institute (NCI)
- BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
Sponsor: Memorial Sloan Kettering Cancer Center
Industry payments
Updated 14 Oct 2026
20 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Daiichi Sankyo Inc.Program year20259 payments$10,846openpaymentsdata.cms.gov ↗
- EMD Serono Research & Development Institute, Inc.Program year20252 payments
- RECORDATI_RARE_DISEASES_INC.Program year20256 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
82.9%Kinase inhibitor82.9%Imatinib Mesylate56%Gleevec15%Verzenio11%Cabometyx10%Votrient8%Part D<11 patientsSensory organs
8.9%Corticosteroid8.9%Dexamethasone100%Part D<11 patientsCardiovascular
8.2%Calcium channel blocker8.2%Amlodipine Besylate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 14 Oct 2026
2 NIH research awards on record, funded 2018–2026 per NIH RePORTER. The latest:
- Improving CDK4/6 inhibition therapy for patients with liposarcoma by understanding resistance
Sloan-Kettering Inst Can Research
FY2026$727,732R01CA296835 - Core C: Clinical Trials and Patient Advocacy
Sloan-Kettering Inst Can Research
FY2026$87,486P50CA217694 - Improving CDK4/6 inhibition therapy for patients with liposarcoma by understanding resistance
Sloan-Kettering Inst Can Research
FY2025$727,732R01CA296835
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcomes in Sarcoma.
Clinical cancer research
Article2026 - Does Longitudinal Targeted Panel Sequencing Provide Clinically Relevant Information in Translocation-Associated Sarcomas?
JCO precision oncology
Article2026 - Deep-Learning Tool ScVital Enables Species-Agnostic Integration of Cancer Cell States.
Cancer research
Article2026 - Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma.
Cancer research communications
Clinical Trial2026 - Spectrum and Clinical Impact of Secondary Genetic Alterations in Translocation-Associated Sarcomas.
JCO precision oncology
Article2025
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/william-tap-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/william-tap-746496191
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗ - X / Twitter
x.com/wtapmd
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗
Mentions by others
where others cite or feature them- Facebook
facebook.com/osteosarcomainstitute/posts/william-tap-md-is-a-medical-oncologist-at-memorial-sloan-kettering-cancer-center/965314612443421
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗ - Other
mskcc.org/videos/meet-medical-oncologist-william-tap
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - X / Twitter
X/Twitter handle @WTapMD
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vivo.weill.cornell.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vivo.weill.cornell.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mskcc.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
- Internal Medicine Residency
Vanderbilt University
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - Medical Oncology/Hematology Fellowship
University of California Los Angeles
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
Editorial & leadership roles
journal and society appointments- Chief
Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vivo.weill.cornell.edu ↗
Media & interviews
press, podcasts and appearances- OncLive video series "Dr. Tap on..."
multiple interviews on precision medicine, GIST, TGCT, soft tissue sarcoma treatment
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
- SARC Talk podcast
inaugural episode, guest alongside Dr. Brian Van Tine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →sarctrials.org ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center
Mark Kris, MD
Memorial Sloan Kettering Cancer Center
George Demetri, MD
Dana-Farber Cancer Institute; Professor of Medicine
Richard Gorlick, MD
The University of Texas MD Anderson Cancer Center
Scott Schuetze, MD
University of Michigan Medical School
Steven Dubois, MD
Dana-Farber/Boston Children's Cancer and Blood Disorders Center; Harvard Medical School